In the last trading session, 1.39 million shares of the Neumora Therapeutics Inc (NASDAQ:NMRA) were traded, and its beta was 3.84. Most recently the company’s share price was $9.86, and it changed around $0.02 or 0.20% from the last close, which brings the market valuation of the company to $1.59B. NMRA currently trades at a discount to its 52-week high of $21.00, offering almost -112.98% off that amount. The share price’s 52-week low was $8.33, which indicates that the current value has risen by an impressive 15.52% since then. We note from Neumora Therapeutics Inc’s average daily trading volume that its 10-day average is 1.22 million shares, with the 3-month average coming to 1.01 million.
Neumora Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended NMRA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Neumora Therapeutics Inc is expected to report earnings per share of -0.4 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Instantly NMRA has showed a green trend with a performance of 0.20% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 11.97 on recent trading dayincreased the stock’s daily price by 17.63%. The company’s shares are currently down -42.17% year-to-date, but still down -12.82% over the last five days. On the other hand, Neumora Therapeutics Inc (NASDAQ:NMRA) is -29.82% down in the 30-day period. We can see from the shorts that 9.37 million shares have been sold at a short interest cover period of 7.45 day(s).
The consensus price target as assigned by Wall Street analysts is $24.5, which translates to bulls needing to increase their stock price by 59.76% from its current value. Analyst projections state that NMRA is forecast to be at a low of $20 and a high of $29.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
Neumora Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 4.34 percent over the past six months and at a 56.47% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 43.28% in revenue this quarter, and will report a decrease of -33.33% in the next quarter.
Forecasts for the next quarter put sales growth at �.
NMRA Dividends
Neumora Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 27.73% of Neumora Therapeutics Inc shares, and 64.25% of them are in the hands of institutional investors. The stock currently has a share float of 88.91%.
